COLL · Collegium Pharmaceutical, Inc
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted earnings per share non-GAAP | $3.67 | Six Months Ended June 30 | — |
|
|
|||
| Adjusted EBITDA non-GAAP | $217.73M | Six Months Ended June 30 | — |
| Adjusted operating expenses non-GAAP | $135.93M | Six Months Ended June 30 | — |
| Adjusted weighted-average shares — diluted non-GAAP | 40,076,322 | Six Months Ended June 30 | — |
| AZSTARYS net revenue | $12.9M | May 12, 2026, to June 30, 2026 | — |
| AZSTARYS prescriptions growth | 1.9% | the 2026 Quarter | — |
| Belbuca net revenue | $57.67M | FY2026 Q2 | +9.6% |
|
|
|||
| Cash from operations | $71.3M | the 2026 Quarter | — |
| JORNAY PM net revenue | $46.06M | FY2026 Q2 | +41.2% |
|
|
|||
| JORNAY PM prescriptions growth | 13.1% | the 2026 Quarter | — |
| Non-GAAP adjusted net income non-GAAP | $144.62M | Six Months Ended June 30 | — |
| Non-GAAP effective tax rates non-GAAP | 17.3% | Three Months Ended June 30 | — |
| Xtampza ER net revenue | $45.01M | FY2026 Q2 | -14.4% |
|
|
|||
| Pain portfolio net revenues | $154.6M | the quarter ended March 31, 2026 | — |
|
|
|||
| Jornay PM prescribers | 29,000 | Q4 2025 | — |
| Jornay PM prescriptions | 760,000 | FY 2025 | — |
| Nucynta Franchise net revenue | $196.3M | FY 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
COLL
this stock
Collegium Pharmaceutical, Inc
|
$919.04M | -39.0% | +23.6% | — | 15.6% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$64.91B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$56.30B | +13.1% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.49B | +2.4% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$42.85B | +17.8% | +4.3% | 60.3 | 2.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| COLL | -4.2% | -21.8% | -37.1% | -20.2% | -39.0% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -4.6% | -26.2% | -50.8% | -24.2% | -52.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.